204 related articles for article (PubMed ID: 21114420)
1. Signal transducer and activator of transcription 3 inhibitors: a patent review.
Page BD; Ball DP; Gunning PT
Expert Opin Ther Pat; 2011 Jan; 21(1):65-83. PubMed ID: 21114420
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report.
Haftchenary S; Avadisian M; Gunning PT
Anticancer Drugs; 2011 Feb; 22(2):115-27. PubMed ID: 21063201
[TBL] [Abstract][Full Text] [Related]
3. Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.
Masciocchi D; Gelain A; Villa S; Meneghetti F; Barlocco D
Future Med Chem; 2011 Apr; 3(5):567-97. PubMed ID: 21526897
[TBL] [Abstract][Full Text] [Related]
4. Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature.
Lavecchia A; Di Giovanni C; Cerchia C
Expert Opin Ther Pat; 2014 Apr; 24(4):383-400. PubMed ID: 24432979
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein.
Debnath B; Xu S; Neamati N
J Med Chem; 2012 Aug; 55(15):6645-68. PubMed ID: 22650325
[No Abstract] [Full Text] [Related]
6. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein.
Fletcher S; Drewry JA; Shahani VM; Page BD; Gunning PT
Biochem Cell Biol; 2009 Dec; 87(6):825-33. PubMed ID: 19935868
[TBL] [Abstract][Full Text] [Related]
7. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.
Mankan AK; Greten FR
Expert Opin Investig Drugs; 2011 Sep; 20(9):1263-75. PubMed ID: 21751940
[TBL] [Abstract][Full Text] [Related]
9. A STAT inhibitor patent review: progress since 2011.
Lai PS; Rosa DA; Magdy Ali A; Gómez-Biagi RF; Ball DP; Shouksmith AE; Gunning PT
Expert Opin Ther Pat; 2015; 25(12):1397-421. PubMed ID: 26394986
[TBL] [Abstract][Full Text] [Related]
10. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.
Kim BH; Yi EH; Ye SK
Arch Pharm Res; 2016 Aug; 39(8):1085-99. PubMed ID: 27515050
[TBL] [Abstract][Full Text] [Related]
11. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution.
Aggarwal BB; Sethi G; Ahn KS; Sandur SK; Pandey MK; Kunnumakkara AB; Sung B; Ichikawa H
Ann N Y Acad Sci; 2006 Dec; 1091():151-69. PubMed ID: 17341611
[TBL] [Abstract][Full Text] [Related]
12. STAT proteins: novel molecular targets for cancer drug discovery.
Turkson J; Jove R
Oncogene; 2000 Dec; 19(56):6613-26. PubMed ID: 11426647
[TBL] [Abstract][Full Text] [Related]
13. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids.
Selvendiran K; Koga H; Ueno T; Yoshida T; Maeyama M; Torimura T; Yano H; Kojiro M; Sata M
Cancer Res; 2006 May; 66(9):4826-34. PubMed ID: 16651438
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1.
Lui VW; Boehm AL; Koppikar P; Leeman RJ; Johnson D; Ogagan M; Childs E; Freilino M; Grandis JR
Mol Pharmacol; 2007 May; 71(5):1435-43. PubMed ID: 17325127
[TBL] [Abstract][Full Text] [Related]
15. STAT 3 as a target for cancer drug discovery.
Costantino L; Barlocco D
Curr Med Chem; 2008; 15(9):834-43. PubMed ID: 18473793
[TBL] [Abstract][Full Text] [Related]
16. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis.
Jing N; Li Y; Xiong W; Sha W; Jing L; Tweardy DJ
Cancer Res; 2004 Sep; 64(18):6603-9. PubMed ID: 15374974
[TBL] [Abstract][Full Text] [Related]
17. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents.
Gelain A; Mori M; Meneghetti F; Villa S
Curr Med Chem; 2019; 26(27):5165-5206. PubMed ID: 30027840
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma.
Page BD; Croucher DC; Li ZH; Haftchenary S; Jimenez-Zepeda VH; Atkinson J; Spagnuolo PA; Wong YL; Colaguori R; Lewis AM; Schimmer AD; Trudel S; Gunning PT
J Med Chem; 2013 Sep; 56(18):7190-200. PubMed ID: 23968501
[TBL] [Abstract][Full Text] [Related]
19. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
[TBL] [Abstract][Full Text] [Related]
20. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy.
Germain D; Frank DA
Clin Cancer Res; 2007 Oct; 13(19):5665-9. PubMed ID: 17908954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
